Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2 Chloro 2' Arabino Fluoro 2' Deoxyadenosine
2. 2 Chloro 2' Fluoroarabino 2' Deoxyadenosine
3. 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
4. 2-chloro-2'-fluoroarabino-2'-deoxyadenosine
5. 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arbinofuranosyl)adenine
6. 2-chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine
7. 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-
8. Cl-f-ara-a
9. Clofarex
10. Clolar
11. Evoltra
1. 123318-82-1
2. Clolar
3. Evoltra
4. Clofarex
5. Cafda
6. Cl-f-ara-a
7. C1-f-ara-a
8. (2r,3r,4s,5r)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
9. 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine
10. 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine
11. Chebi:681569
12. (2r,3r,4s,5r)-5-(6-amino-2-chloro-9h-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
13. 762rdy0y2h
14. 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-
15. (2r,3r,4s,5r)-5-(6-amino-2-chloro-9h-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
16. Nsc-759857
17. Clofarabine [usan]
18. 2-chloro-9-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)adenine
19. Dsstox_cid_26437
20. Dsstox_rid_81613
21. Dsstox_gsid_46437
22. Cfb
23. Clofarabina
24. Clofarabinum
25. Cl-f-araa
26. Mfcd00871077
27. 2-chloro-9-(2-deoxy-2-fluoro-b -d-arabinofuranosyl)-9h-purin-6-amine
28. (2r,3r,4s,5r)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
29. Clolar (tn)
30. Cas-123318-82-1
31. 2-cl-2'-f-araa
32. Unii-762rdy0y2h
33. Clofarabine [usan:inn:ban]
34. Ncgc00164553-01
35. Clofarabine [mi]
36. Clofarabine [inn]
37. Clofarabine [jan]
38. 2-chloro-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl)-9h-purin-6-amine
39. 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
40. Clofarabine [vandf]
41. Clofarabine,clolar, Evoltra
42. Schembl9040
43. Chembl1750
44. Clofarabine [mart.]
45. Clofarabine [who-dd]
46. Mls003915615
47. Clofarabine (jan/usan/inn)
48. Clofarabine [ema Epar]
49. Gtpl6802
50. Dtxsid5046437
51. Clofarabine, >=98% (hplc)
52. Clofarabine [orange Book]
53. Hms2090a07
54. Hms3413j15
55. Hms3677j15
56. Act05522
57. Bcp23422
58. Hy-a0005
59. Zinc3798247
60. Tox21_112182
61. Ac-274
62. Bdbm50247921
63. S1218
64. Akos005063562
65. Akos015919355
66. Tox21_112182_1
67. Bcp9000540
68. Ccg-264865
69. Cs-0373
70. Db00631
71. Nsc 759857
72. Sar-393590
73. Ncgc00164553-02
74. Ncgc00164553-05
75. As-12958
76. Smr002530055
77. Bcp0726000280
78. Sw218080-2
79. D03546
80. Ab00430247-03
81. Ab00430247-04
82. Ab00430247_06
83. 318c821
84. Sr-01000930565
85. Q5134875
86. Sr-01000930565-3
87. Z1557400138
88. 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine
89. 2-chloro-9-(2-deoxy-2-fluoro-?-d-arabinofuranosyl)-9h-purin-6-amine
90. 9h-purine-6-amine,2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-
91. 2-chloro-9-(2-deoxy-2-fluoro-.beta.-d-arabinofuranosyl)-9h-purin-6-amine
92. 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-.beta.-d-arabinofuranosyl)
93. (2r,3r,4s,5r)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol 2-chloro-2''-arabino-fluoro-2''-deoxyadenosine
Molecular Weight | 303.68 g/mol |
---|---|
Molecular Formula | C10H11ClFN5O3 |
XLogP3 | 0.9 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 2 |
Exact Mass | 303.0534451 g/mol |
Monoisotopic Mass | 303.0534451 g/mol |
Topological Polar Surface Area | 119 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 370 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Clolar |
PubMed Health | Clofarabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Clolar (clofarabine) Injection contains clofarabine, a purine nucleoside metabolic inhibitor. Clolar (1 mg/mL) is supplied in a 20 mL, single-use vial. The 20 mL vial contains 20 mg clofarabine formulated in 20 mL unbuffered normal saline (comprised... |
Active Ingredient | Clofarabine |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | 20mg/20ml (1mg/ml) |
Market Status | Prescription |
Company | Genzyme |
2 of 2 | |
---|---|
Drug Name | Clolar |
PubMed Health | Clofarabine (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Clolar (clofarabine) Injection contains clofarabine, a purine nucleoside metabolic inhibitor. Clolar (1 mg/mL) is supplied in a 20 mL, single-use vial. The 20 mL vial contains 20 mg clofarabine formulated in 20 mL unbuffered normal saline (comprised... |
Active Ingredient | Clofarabine |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | 20mg/20ml (1mg/ml) |
Market Status | Prescription |
Company | Genzyme |
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
FDA Label
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients 21 years old at initial diagnosis.
Clofarabine is a purine nucleoside antimetabolite that differs from other puring nucleoside analogs by the presence of a chlorine in the purine ring and a flourine in the ribose moiety. Clofarabine seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by clofarabine, other effects also occur. Clofarabine prevents cells from making DNA and RNA by interfering with the synthesis of nucleic acids, thus stopping the growth of cancer cells.
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
L01BB06
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01B - Antimetabolites
L01BB - Purine analogues
L01BB06 - Clofarabine
Route of Elimination
Based on 24-hour urine collections in the pediatric studies, 49 - 60% of the dose is excreted in the urine unchanged.
Volume of Distribution
172 L/m2
Clearance
28.8 L/h/m2 [Pediatric patients (2 - 19 years old) with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) receiving 52 mg/m2 dose]
Clofarabine is sequentially metabolized intracellularly to the 5’-monophosphate metabolite by deoxycytidine kinase and mono- and di-phosphokinases to the active 5’-triphosphate metabolite. Clofarabine has high affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine.
The terminal half-life is estimated to be 5.2 hours.
Clofarabine is metabolized intracellularly to the active 5'-monophosphate metabolite by deoxycytidine kinase and 5'-triphosphate metabolite by mono- and di-phospho-kinases. This metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through competitive inhibition of DNA polymerases. This leads to the depletion of the intracellular deoxynucleotide triphosphate pool and the self-potentiation of clofarabine triphosphate incorporation into DNA, thereby intensifying the effectiveness of DNA synthesis inhibition. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5'-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading to programmed cell death.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Clofarabine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clofarabine, including repackagers and relabelers. The FDA regulates Clofarabine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clofarabine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clofarabine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clofarabine supplier is an individual or a company that provides Clofarabine active pharmaceutical ingredient (API) or Clofarabine finished formulations upon request. The Clofarabine suppliers may include Clofarabine API manufacturers, exporters, distributors and traders.
click here to find a list of Clofarabine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Clofarabine DMF (Drug Master File) is a document detailing the whole manufacturing process of Clofarabine active pharmaceutical ingredient (API) in detail. Different forms of Clofarabine DMFs exist exist since differing nations have different regulations, such as Clofarabine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Clofarabine DMF submitted to regulatory agencies in the US is known as a USDMF. Clofarabine USDMF includes data on Clofarabine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Clofarabine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Clofarabine suppliers with USDMF on PharmaCompass.
A Clofarabine written confirmation (Clofarabine WC) is an official document issued by a regulatory agency to a Clofarabine manufacturer, verifying that the manufacturing facility of a Clofarabine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clofarabine APIs or Clofarabine finished pharmaceutical products to another nation, regulatory agencies frequently require a Clofarabine WC (written confirmation) as part of the regulatory process.
click here to find a list of Clofarabine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clofarabine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clofarabine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clofarabine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clofarabine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clofarabine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clofarabine suppliers with NDC on PharmaCompass.
Clofarabine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clofarabine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clofarabine GMP manufacturer or Clofarabine GMP API supplier for your needs.
A Clofarabine CoA (Certificate of Analysis) is a formal document that attests to Clofarabine's compliance with Clofarabine specifications and serves as a tool for batch-level quality control.
Clofarabine CoA mostly includes findings from lab analyses of a specific batch. For each Clofarabine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clofarabine may be tested according to a variety of international standards, such as European Pharmacopoeia (Clofarabine EP), Clofarabine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clofarabine USP).
LOOKING FOR A SUPPLIER?